Gene-Targeted Drug Tagrisso Cuts Death Rate in Half for Patients With Early-Stage Lung Cancer
TUESDAY, June 6, 2023 (HealthDay News) — Once-a-day use of the targeted cancer pill Tagrisso (osimertinib) cut the five-year death rate in half for a subset of patients with early-stage lung cancer, a new clinical trial shows.The results could have m…
Learn MoreASCO: Germline Testing Underused in Cancer Patients
TUESDAY, June 6, 2023 (HealthDay News) — Few patients diagnosed with cancer between 2013 and 2019 in California and Georgia underwent germline testing, according to a study published online June 5 in the Journal of the American Medical Association to…
Learn MoreASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC
TUESDAY, June 6, 2023 (HealthDay News) — For patients with advanced non-small cell lung cancer (NSCLC), indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for two years, according to a study pub…
Learn MoreInjected Birth Control Could Be Game-Changer to Curb Stray Cat Populations
TUESDAY, June 6, 2023 (HealthDay News) — Millions of stray cats roam the world over, and surgical sterilization has long been the primary method of population control.But a small new study shows promising results for a one-and-done contraceptive inje…
Learn MoreNirmatrelvir-Ritonavir Effective for Outpatient Treatment of COVID-19
TUESDAY, June 6, 2023 (HealthDay News) — For outpatient treatment of COVID-19, nirmatrelvir-ritonavir is effective for reducing 30-day hospitalization or death, while molnupiravir is associated with a reduction in 30-day mortality, according to a stu…
Learn MoreReview Compares Diagnostic Strategies for Assessment of Coronary Artery Disease
TUESDAY, June 6, 2023 (HealthDay News) — Coronary computed tomography angiography (CCTA) is associated with a similar risk for cardiovascular death and myocardial infarction as direct invasive coronary angiography (ICA) for initial assessment of susp…
Learn MoreASCO: Vorasidenib Improves Progression-Free Survival in Grade 2 IDH-Mutant Glioma
TUESDAY, June 6, 2023 (HealthDay News) — Vorasidenib significantly improves progression-free survival among patients with grade 2 isocitrate dehydrogenase (IDH)-mutant glioma, according to a study published online June 4 in the New England Journal of…
Learn MoreASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
TUESDAY, June 6, 2023 (HealthDay News) — Direct oral anticoagulant (DOAC) treatment is noninferior to low-molecular-weight heparin (LMWH) for preventing recurrent venous thromboembolism (VTE) in cancer patients, according to a study published online …
Learn MoreLow-Dose Atropine Treatment Slows Pediatric Myopia Progression
TUESDAY, June 6, 2023 (HealthDay News) — Low-dose atropine treatment reduces pediatric myopia progression compared with placebo over three years of treatment, according to a study published online June 1 in JAMA Ophthalmology.Karla Zadnik, O.D., Ph.D…
Learn MoreCertain Factors Increase Risk for UTIs After Radical Hysterectomies
TUESDAY, June 6, 2023 (HealthDay News) — Smoking and using a catheter for more than seven days postsurgery significantly increase the risk for catheter-associated urinary tract infections after radical hysterectomies for cervical cancer, according to…
Learn More